Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin plus anlotinib for refractory advanced soft tissue sarcoma
ChiCTR2200059629Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and anlotinib in soft tissue sarcoma (STS), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started May 2022; status: recruiting.
02
Drugs
eribulinanlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2200059629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059629.